WilliamPaulPetersMD

PubMed

• 78 citations
  High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials
  Donald A. Berry, Naoto T. Ueno, Marcella M. Johnson, Xiudong Lei, Jean Caputo, Sjoerd Rodenhuis, William P. Peters, Robert C. F. Leonard, William E. Barlow, Martin S. ...> ;Journal of Clinical Oncology. 2011 Aug 20
• 5 citations
  Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatoc...
  Gilberto Lopes, Jennifer S. Dicksey, William P. Peters, Melvin Palalay, Alex Y. Chang> ;Cancer Chemotherapy and Pharmacology. 2011 Feb 23
• 18 citations
  Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9...
  Lawrence B. Marks, Constance Cirrincione, Thomas J. Fitzgerald, F. Laurie, Arvin S. Glicksman, James J. Vredenburgh, Leonard R. Prosnitz, Elizabeth J. Shpall, Michael ...> ;International Journal of Radiation Oncology, Biology, Physics. 2010 Apr 1
• 44 citations
  A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
  Georgia M. Beasley, Nicole McMahon, Gretchen Sanders, Christina K. Augustine, Maria Angelica Selim, Bercedis Peterson, Robin J. Norris, William P. Peters, Merrick I. R...> ;Cancer. 2009 Oct 15
• A prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma.
  Beasley G, Sanders G, Zager JS, Hochwald SN, Grobmyer S, Andtbacka RH, Peterson B, Peters WP, Ross MI, Tyler DS> ;J. Clin. Oncol.. 2009-05-20
• Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
  Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters W...> ;Ann. Oncol.. 2009-04-01
• 1 citations
  Cooperative groups are not...
  William P. Peters> ;Archives of Internal Medicine. 2008 Oct 27
• A phase I/II study of systemic ADH-1 in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma.
  Beasley G, McMahon N, Sanders G, Zipfel P, Augustine C, Petros W, Padussis J, Ross MI, Selim A, Peters W, Tyler DS> ;J. Clin. Oncol.. 2008-05-20
• An open label phase I dose escalation study of ADH-1 in combination with chemotherapy in subjects with N-Cadherin expressing solid tumors.
  Raju RN, Alemany C, Basche M, Garbo LE, Richards DA, Smith DA, Stephenson JJ, Norris R, Lawton M, Peters W, Becerra CR> ;J. Clin. Oncol.. 2008-05-20
• A phase I study evaluating a novel schedule of oral eniluracil (EU) combined with escalating doses of oral 5-fluorouracil (5- FU).
  Murphy PB, Raefsky E, Burris HA, Infante JR, Jones SF, Spigel DR, Dickson N, Lawton M, Dicksey JS, Peters WP> ;J. Clin. Oncol.. 2008-05-20
• 86 citations
  Targeting N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma Treatment
  Christina K. Augustine, Yasunori Yoshimoto, Mukur Gupta, Patricia A. Zipfel, M. Angelica Selim, Phillip G. Febbo, Ann Marie Pendergast, William P. Peters, Douglas S. T...> ;Cancer Research. 2008 May 15
• Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tum...
  Stewart DJ, Jonker DJ, Goel R, Goss G, Maroun JA, Cripps CM, Wells J, Wargin W, Malik RK, Peters WP> ;J. Clin. Oncol.. 2006-06-20
• An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors.
  Sessa C, Perotti A, Maur M, Fasolo A, Scaramuzza D, Braghetti A, Marsoni S, Malik RK, Peters WP, Gianni L> ;J. Clin. Oncol.. 2006-06-20
• 27 citations
  A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to obs...
  James J. Vredenburgh, B Madan, David Coniglio, Maureen Ross, Gloria Broadwater, Donna Niedzwiecki, Jon Edwards, Lawrence B. Marks, Robert M. Vandemark, Carolyn McDonal...> ;Bone Marrow Transplantation. 2006 Jun 1
• 27 citations
  Consolidation with High-Dose Combination Alkylating Agents with Bone Marrow Transplantation Significantly Improves Disease-Free Survival in Hormone-Insensitive Metasta...
  James J. Vredenburgh, David Coniglio, Gloria Broadwater, Roy B. Jones, Maureen Ross, Elizabeth J. Shpall, A. Hussein, David A. Rizzieri, Lawrence B. Marks, Colleen J. ...> ;Biology of Blood and Marrow Transplantation. 2006 Feb 1
• 25 citations
  Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-...
  Jeffrey Peppercorn, James E. Herndon, Alice B. Kornblith, William P. Peters, Tim A. Ahles, James J. Vredenburgh, Gary N. Schwartz, Elizabeth J. Shpall, David D. Hurd, ...> ;Cancer. 2005 Oct 15
• 86 citations
  Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer
  William P. Petros, Penelope J. Hopkins, Susan Spruill, Gloria Broadwater, James J. Vredenburgh, O. Michael Colvin, William P. Peters, Roy B. Jones, Jeff Hall, Jeffrey ...> ;Journal of Clinical Oncology. 2005 Sep 1
• A phase I study of the novel molecularly targeted vascular targeting agent, Exherin (ADH-1), shows activity in some patients with refractory solid tumors stratified ac...
  Jonker DJ, Stewart DJ, Goel R, Avruch L, Goss G, Maroun J, Cripps C, Wells J, Malik RK, Peters WP> ;J. Clin. Oncol.. 2005-06-01
• 78 citations
  Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Wo...
  William P. Peters, Gary L. Rosner, James J. Vredenburgh, Elizabeth J. Shpall, Michael Crump, Paul G. Richardson, Michael W. Schuster, Lawrence B. Marks, Constance Cirr...> ;Journal of Clinical Oncology. 2005 Apr 1
• 36 citations
  Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
  Emilio Bria, Diana Giannarelli, Alessandra Felici, William P. Peters, Cecilia Nistico, Barbara Vanni, Federica Cuppone, Francesco Cognetti, Edmondo Terzoli> ;Cancer. 2005 Feb 15
• A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin express...
  Jonker DJ, Avruch L, Stewart DJ, Goel R, Goss G, Dent S, Reaume MN, Spencer TA, Peters WP> ;J. Clin. Oncol.. 2004-07-15
• 9 citations
  Dose Density by Any Other Name
  William Hryniuk, Joseph Ragaz, William P. Peters> ;Journal of Clinical Oncology. 2004 Feb 15
• 12 citations
  Cost-effectiveness and lung cancer clinical trials
  Wei Du, Jaxk Reeves, Shirish Gadgeel, Judith Abrams, William P. Peters> ;Cancer. 2003 Oct 1
• 3 citations
  High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
  Monic J. Stuart, William P. Peters, Gloria Broadwater, A. Hussein, Maureen Ross, Lawrence B Marks, Rodney J Folz, Gwynn D. Long, David A. Rizzieri, Nelson J. Chao, Jam...> ;Biology of Blood and Marrow Transplantation. 2002 Dec 1
• 42 citations
  Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer
  William P. Petros, Gloria Broadwater, Donald A. Berry, Roy B. Jones, James J. Vredenburgh, Colleen J. Gilbert, John P. Gibbs, O. Michael Colvin, William P. Peters> ;Clinical Cancer Research. 2002 Mar 1
• Join now to see all